Eidos Therapeutics, Inc, based in San Francisco, CA, is an affiliate of BridgeBio Pharma that is dedicated to improving the lives of patients with transthyretin amyloidosis (ATTR), a rare and life-threatening disease with limited treatment options. Through their research and development efforts, Eidos Therapeutics aims to discover and develop a novel therapeutic for ATTR, focusing on ATTR cardiomyopathy (ATTR-CM), a form of amyloidosis that affects the heart and can significantly impact patients' quality of life and life expectancy.
With a deep understanding of the role of transthyretin (TTR) protein in the disease, Eidos Therapeutics is committed to addressing the underdiagnosis and limited treatment options for ATTR-CM. By leveraging scientific advancements and their expertise, they strive to provide innovative solutions that can improve the morbidity and mortality of patients with this devastating condition.
Generated from the website
